Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors

NCT06475937 is registered in ClinicalTrials.gov with Xadcera Biopharmaceutical (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT06475937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06475937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients With Advanced Solid Tumors
Lead sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 24, 2024
Completion date
May 31, 2027
Enrollment
128 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, carcinoma, non-small-cell lung, solid carcinoma